Notice of in-court restructuring proceedings of Orphazyme A/S
March 18, 2022 06:40 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 11/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Commencement of in-court restructuring of Orphazyme A/S
March 10, 2022 16:05 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Will institute a reduction of approximately 50% of current work forceIntends to...
Updated Financial Calender for 2022
March 03, 2022 03:35 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Anders Vadsholt takes over as CEO of Orphazyme
February 28, 2022 02:25 ET
|
ORPHAZYME A/S
Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Orphazyme announces update on regulatory review of arimoclomol in the European Union
February 23, 2022 16:05 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))...
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
February 18, 2022 16:01 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a...
Resolutions passed at the Extraordinary General Meeting
February 15, 2022 12:15 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Amendment of proposals put forward at the Extraordinary General Meeting
February 14, 2022 16:01 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
February 11, 2022 01:50 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor newsNo. 02/2022www.orphazyme.comCompany Registration No. 32266355 Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a...
Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™
February 07, 2022 06:22 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor NewsNo. 01/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 7, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...